Release Details
Cerulean Announces Clinical Collaboration with AstraZeneca and the National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101
Three-Party Collaboration Will Explore Synergies Between AstraZeneca's Leading PARP Inhibitor and Cerulean's Topoisomerase Inhibitor
"The discovery of new, therapeutic combinations that improve patient
outcomes is a core part of our strategy. The combination of LYNPARZA
with CRLX101 provides an opportunity to investigate the potential of
LYNPARZA beyond patients with mutations in homologous repair genes such
as BRCA," said
"Cerulean's nanoparticle-drug conjugates, or NDCs, are suited to enable
therapeutic combinations because they are designed to concentrate
anti-cancer payloads inside tumor cells and spare healthy tissue," said
The scientific rationale for combining PARP inhibitors with Top1 inhibitors is well understood. Simply stated, Top1 inhibitors damage DNA, and PARP inhibitors prevent DNA damage repair. CRLX101 is a Top1 inhibitor. Top1 inhibitors trap DNA-topoisomerase complexes, preventing ligation and resulting in persistent single-stranded breaks. LYNPARZA is a PARP inhibitor that exploits tumor DNA damage repair pathway deficiencies to preferentially kill cancer cells. PARP's main role is to detect and signal single-strand DNA breaks to the enzymatic complex that repairs single-strand DNA breaks.
Under this collaboration, AstraZeneca will supply LYNPARZA, Cerulean
will supply CRLX101, and the NCI will fund and conduct the clinical
trial under
About CRLX101
CRLX101 is a nanoparticle-drug conjugate (NDC) designed to concentrate
in tumors and slowly release its anti-cancer payload, camptothecin,
inside tumor cells. CRLX101 inhibits topoisomerase I (Top1), which is
involved in cellular replication and transcription, and also inhibits
hypoxia-inducible factor-1α (HIF-1α), which research suggests is a
master regulator of cancer cell survival mechanisms. CRLX101 has shown
activity in four different tumor types, both as monotherapy and in
combination with other cancer treatments. CRLX101 is in Phase 2 clinical
development and has been dosed in more than 300 patients. The U.S.
About LYNPARZA (olaparib)
LYNPARZA is an innovative, first-in-class oral poly ADP-ribose
polymerase (PARP) inhibitor that exploits tumour DNA repair pathway
deficiencies to preferentially kill cancer cells. This mode of action
gives LYNPARZA the potential for activity in a range of tumour types
with DNA repair deficiencies. LYNPARZA is the first PARP inhibitor to be
approved for patients with germline BRCA-mutated advanced ovarian
cancer, and has been launched in the U.S. and
About
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial. For more information, please visit www.ceruleanrx.com.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about the clinical development
of our product candidates, statements about our estimated research and
development expenses and sufficiency of cash to fund specified use of
cash and other statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "hypothesize," "intend,"
"may," "plan," "potential," "predict," "project," "should," "target,"
"would," and similar expressions, constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including: the uncertainties inherent in the initiation of clinical
trials, availability and timing of data from ongoing and future clinical
trials and the results of such trials, whether preliminary results from
a clinical trial will be predictive of the final results of that trial
or whether results of early clinical trials will be indicative of the
results of later clinical trials, expectations for regulatory approvals,
availability of funding sufficient for our foreseeable and unforeseeable
operating expenses and capital expenditure requirements and other
factors discussed in the "Risk Factors" section of our Quarterly Report
on Form 10-Q filed with the
Avastin is a registered trademark of
LYNPARZA is a trademark of the AstraZeneca group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151117005535/en/
Director,
Investor Relations and Corporate Communications
[email protected]
Source:
News Provided by Acquire Media